Veeva Shares Poised for 30% Rally, Say Wall Street Analysts
Veeva Systems Inc., VEEV, an enterprise software provider specializing in solutions for pharmaceutical and biotechnology organizations, has seen its shares trade near $285. This marks a significant decline from the 2021 peak of $344.
Despite this decline, Wall Street analysts believe that the stock has substantial room for recovery and growth, projecting potential gains of 30% within the next year.
The company's proprietary Veeva Vault CRM solution is gaining traction, with 14 out of the world's top 20 biopharma companies already on board. This transition from Salesforce infrastructure to its own platform enables Veeva to improve profitability through better margin control and eliminates dependence on a rival's technology foundation.
The company's latest innovation, the Falcon suite, leverages agentic AI to streamline medical and regulatory processes, potentially reducing manual workflows by as much as 70%. According to Gartner forecasts, worldwide investment in specialized AI agents will more than double annually through 2029, exceeding $750 billion in market value.